Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
An Agentic Framework for Rapid Deployment of Edge AI Solutions in Industry 5.0
arXiv:2510.25813v1 Announce Type: new Abstract: We present a novel framework for Industry 5.0 that simplifies the deployment of AI models on edge devices in various industrial settings. The design reduces latency and avoids external data transfer by enabling local inference and real-time processing. Our implementation is agent-based, which means that individual agents, whether human, algorithmic, or collaborative, are responsible for well-defined tasks, enabling flexibility and simplifying inte
-
cs.AI, q-bio.NC updates on arXiv.org
-
Identity Management for Agentic AI: The new frontier of authorization, authentication, and security for an AI agent world
arXiv:2510.25819v1 Announce Type: cross Abstract: The rapid rise of AI agents presents urgent challenges in authentication, authorization, and identity management. Current agent-centric protocols (like MCP) highlight the demand for clarified best practices in authentication and authorization. Looking ahead, ambitions for highly autonomous agents raise complex long-term questions regarding scalable access control, agent-centric identities, AI workload differentiation, and delegated authority. Th
Identity Management for Agentic AI: The new frontier of authorization, authentication, and security for an AI agent world
-
cs.AI, q-bio.NC updates on arXiv.org
-
Supervised Reinforcement Learning: From Expert Trajectories to Step-wise Reasoning
arXiv:2510.25992v1 Announce Type: cross Abstract: Large Language Models (LLMs) often struggle with problems that require multi-step reasoning. For small-scale open-source models, Reinforcement Learning with Verifiable Rewards (RLVR) fails when correct solutions are rarely sampled even after many attempts, while Supervised Fine-Tuning (SFT) tends to overfit long demonstrations through rigid token-by-token imitation. To address this gap, we propose Supervised Reinforcement Learning (SRL), a frame
Supervised Reinforcement Learning: From Expert Trajectories to Step-wise Reasoning
-
cs.AI, q-bio.NC updates on arXiv.org
-
The Quest for Reliable Metrics of Responsible AI
arXiv:2510.26007v1 Announce Type: cross Abstract: The development of Artificial Intelligence (AI), including AI in Science (AIS), should be done following the principles of responsible AI. Progress in responsible AI is often quantified through evaluation metrics, yet there has been less work on assessing the robustness and reliability of the metrics themselves. We reflect on prior work that examines the robustness of fairness metrics for recommender systems as a type of AI application and summa
The Quest for Reliable Metrics of Responsible AI
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-Agent Evolve: LLM Self-Improve through Co-evolution
arXiv:2510.23595v3 Announce Type: replace Abstract: Reinforcement Learning (RL) has demonstrated significant potential in enhancing the reasoning capabilities of large language models (LLMs). However, the success of RL for LLMs heavily relies on human-curated datasets and verifiable rewards, which limit their scalability and generality. Recent Self-Play RL methods, inspired by the success of the paradigm in games and Go, aim to enhance LLM reasoning capabilities without human-annotated data. Ho
Multi-Agent Evolve: LLM Self-Improve through Co-evolution
-
cs.AI, q-bio.NC updates on arXiv.org
-
Chain-of-Scrutiny: Detecting Backdoor Attacks for Large Language Models
arXiv:2406.05948v4 Announce Type: replace-cross Abstract: Large Language Models (LLMs), especially those accessed via APIs, have demonstrated impressive capabilities across various domains. However, users without technical expertise often turn to (untrustworthy) third-party services, such as prompt engineering, to enhance their LLM experience, creating vulnerabilities to adversarial threats like backdoor attacks. Backdoor-compromised LLMs generate malicious outputs to users when inputs contain
Chain-of-Scrutiny: Detecting Backdoor Attacks for Large Language Models
-
cs.AI, q-bio.NC updates on arXiv.org
-
Vital Insight: Assisting Experts' Context-Driven Sensemaking of Multi-modal Personal Tracking Data Using Visualization and Human-In-The-Loop LLM
arXiv:2410.14879v4 Announce Type: replace-cross Abstract: Passive tracking methods, such as phone and wearable sensing, have become dominant in monitoring human behaviors in modern ubiquitous computing studies. While there have been significant advances in machine-learning approaches to translate periods of raw sensor data to model momentary behaviors, (e.g., physical activity recognition), there still remains a significant gap in the translation of these sensing streams into meaningful, high-l
Vital Insight: Assisting Experts' Context-Driven Sensemaking of Multi-modal Personal Tracking Data Using Visualization and Human-In-The-Loop LLM
-
cs.AI, q-bio.NC updates on arXiv.org
-
Epistemic Diversity and Knowledge Collapse in Large Language Models
arXiv:2510.04226v4 Announce Type: replace-cross Abstract: Large language models (LLMs) tend to generate lexically, semantically, and stylistically homogenous texts. This poses a risk of knowledge collapse, where homogenous LLMs mediate a shrinking in the range of accessible information over time. Existing works on homogenization are limited by a focus on closed-ended multiple-choice setups or fuzzy semantic features, and do not look at trends across time and cultural contexts. To overcome this,
Epistemic Diversity and Knowledge Collapse in Large Language Models
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v2 Announce Type: replace-cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositio
Integrating Genomics into Multimodal EHR Foundation Models
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Nanomaterial-assisted immunodiagnostic profiling and therapeutic targeting of hepatocellular carcinoma: from molecular biomarkers to clinical applications
Front Immunol. 2025 Oct 14;16:1668630. doi: 10.3389/fimmu.2025.1668630. eCollection 2025.ABSTRACTAIMS AND OBJECTIVES: This study aimed to identify immunologically relevant transcriptomic and proteomic biomarkers in hepatocellular carcinoma (HCC) and to characterize their B-cell epitopes for potential integration into nanomaterial-based biosensors and immunomodulatory platforms for early diagnosis and targeted therapy.METHODS: We conducted a comprehensive multi-omics analysis by integrating trans
Nanomaterial-assisted immunodiagnostic profiling and therapeutic targeting of hepatocellular carcinoma: from molecular biomarkers to clinical applications
Front Immunol. 2025 Oct 14;16:1668630. doi: 10.3389/fimmu.2025.1668630. eCollection 2025.
ABSTRACT
AIMS AND OBJECTIVES: This study aimed to identify immunologically relevant transcriptomic and proteomic biomarkers in hepatocellular carcinoma (HCC) and to characterize their B-cell epitopes for potential integration into nanomaterial-based biosensors and immunomodulatory platforms for early diagnosis and targeted therapy.
METHODS: We conducted a comprehensive multi-omics analysis by integrating transcriptomic (TCGA-LIHC) and proteomic data to identify differentially expressed genes (DEGs) in HCC. Protein-protein interaction networks and pathway enrichment were used to prioritize hub genes. Five candidate biomarkers, RFC2, HSP90AB1, YWHAZ, CYP2E1, and ADH4, were selected for qRT-PCR and serum ELISA validation in clinical cohorts comprising 85 HCC patients and 50 healthy controls. B-cell epitope prediction was performed using BepiPred 2.0 and validated through synthetic peptide-based ELISA in the same cohort to assess immunoreactivity. Diagnostic performance was evaluated using ROC curve analysis.
RESULTS: RFC2, HSP90AB1, and YWHAZ were significantly upregulated (|log2FC|>0.2) and showed high serological expression, whereas CYP2E1 and ADH4 were consistently downregulated. Predicted B-cell epitopes from RFC2, HSP90AB1, and YWHAZ exhibited strong immunoreactivity (AUC>0.84), indicating their diagnostic potential. Enrichment analysis revealed that upregulated DEGs were involved in cell cycle and mitotic progression, while downregulated genes were linked to immune suppression and metabolic dysfunction. These validated immunogenic epitopes offer promising anchors for nanomaterial-functionalized biosensors, such as gold nanoparticle-conjugated ELISA, graphene-based electrochemical platforms, and peptide-coated quantum dots, for ultrasensitive and multiplexed HCC detection.
CONCLUSION: By integrating transcriptomic and proteomic screening with epitope-level validation, we identified a novel panel of immunogenic biomarkers suitable for nanomaterial-enabled diagnostics in HCC. These findings support the translational potential of peptide-nano scaffold conjugates in developing minimally invasive, immune-responsive biosensing and therapeutic tools tailored for early-stage liver cancer management.
PMID:41164201 | PMC:PMC12558944 | DOI:10.3389/fimmu.2025.1668630
-
npj Digital Medicine
-
Toward governance of artificial intelligence in pediatric healthcare
npj Digital Medicine, Published online: 30 October 2025; doi:10.1038/s41746-025-02000-7Toward governance of artificial intelligence in pediatric healthcare
Toward governance of artificial intelligence in pediatric healthcare
npj Digital Medicine, Published online: 30 October 2025; doi:10.1038/s41746-025-02000-7
Toward governance of artificial intelligence in pediatric healthcare-
MIT Technology Review

-
Building a high performance data and AI organization (2nd edition)
Four years is a lifetime when it comes to artificial intelligence. Since the first edition of this study was published in 2021, AI’s capabilities have been advancing at speed, and the advances have not slowed since generative AI’s breakthrough. For example, multimodality— the ability to process information not only as text but also as audio, video, and other unstructured formats—is becoming a common feature of AI models. AI’s capacity to reason and act autonomously has also grown, and organizati
Building a high performance data and AI organization (2nd edition)
Four years is a lifetime when it comes to artificial intelligence. Since the first edition of this study was published in 2021, AI’s capabilities have been advancing at speed, and the advances have not slowed since generative AI’s breakthrough. For example, multimodality— the ability to process information not only as text but also as audio, video, and other unstructured formats—is becoming a common feature of AI models. AI’s capacity to reason and act autonomously has also grown, and organizations are now starting to work with AI agents that can do just that.
Amid all the change, there remains a constant: the quality of an AI model’s outputs is only ever as good as the data
that feeds it. Data management technologies and practices have also been advancing, but the second edition of this study suggests that most organizations are not leveraging those fast enough to keep up with AI’s development. As a result of that and other hindrances, relatively few organizations are delivering the desired business results from their AI strategy. No more than 2% of senior executives we surveyed rate their organizations highly in terms of delivering results from AI.

To determine the extent to which organizational data performance has improved as generative AI and other AI advances have taken hold, MIT Technology Review Insights surveyed 800 senior data and technology executives. We also conducted in-depth interviews with 15 technology and business leaders.

Key findings from the report include the following:
• Few data teams are keeping pace with AI. Organizations are doing no better today at delivering on data strategy than in pre-generative AI days. Among those surveyed in 2025, 12% are self-assessed data “high achievers” compared with 13% in 2021. Shortages of skilled talent remain a constraint, but teams also struggle with accessing fresh data, tracing lineage, and dealing with security complexity—important requirements for AI success.
• Partly as a result, AI is not fully firing yet. There are even fewer “high achievers” when it comes to AI. Just 2% of respondents rate their organizations’ AI performance highly today in terms of delivering measurable business results. In fact, most are still struggling to scale generative AI. While two thirds have deployed it, only 7% have done so widely.
This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. AI tools that may have been used were limited to secondary production processes that passed thorough human review.
-
Nature - Issue - nature.com science feeds
-
Multi-omic profiling reveals age-related immune dynamics in healthy adults
Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09686-5This multi-omic longitudinal analysis of the healthy human peripheral immune system constructs the Human Immune Health Atlas and assembles data on immune cell composition and state changes with age, including responses to cytomegalovirus infection and influenza vaccination.
Multi-omic profiling reveals age-related immune dynamics in healthy adults
Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09686-5
This multi-omic longitudinal analysis of the healthy human peripheral immune system constructs the Human Immune Health Atlas and assembles data on immune cell composition and state changes with age, including responses to cytomegalovirus infection and influenza vaccination.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics
Diagnostics (Basel). 2025 Oct 14;15(20):2586. doi: 10.3390/diagnostics15202586.ABSTRACTThe integration of multi-omics technologies is transforming the landscape of cancer management, offering unprecedented insights into tumor biology, early diagnosis, and personalized therapy. This review provides a comprehensive overview of the current state of omics approaches, with a particular focus on the application of genomics, NMR-based metabolomics, and radiomics in non-small cell lung cancer (NSCLC). G
Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics
Diagnostics (Basel). 2025 Oct 14;15(20):2586. doi: 10.3390/diagnostics15202586.
ABSTRACT
The integration of multi-omics technologies is transforming the landscape of cancer management, offering unprecedented insights into tumor biology, early diagnosis, and personalized therapy. This review provides a comprehensive overview of the current state of omics approaches, with a particular focus on the application of genomics, NMR-based metabolomics, and radiomics in non-small cell lung cancer (NSCLC). Genomics currently represents one of the most established omics technologies in oncology, as it enables the identification of genetic alterations that drive tumor initiation, progression, and therapeutic response. Interestingly, genomic analyses have revealed that many tumors harbor mutations in genes encoding metabolic enzymes, thus establishing a tight connection between genomics and tumor metabolism. In parallel, metabolomics profiling-by capturing the metabolic phenotype of tumors-has, in recent years, identified specific biomarkers associated with tumor burden, progression, and prognosis. Such findings have catalyzed growing interest in metabolomics as a complementary approach to better characterize cancer biology and discover novel diagnostic and therapeutic targets. Moreover, radiomics, through the extraction of quantitative features from standard imaging modalities, captures tumor heterogeneity and contributes predictive information on tumor biology, treatment response, and clinical outcomes. As a non-invasive and widely available technique, radiomics has the potential to support longitudinal monitoring and individualized treatment planning. Both metabolomics and radiomics, when integrated with genomic data, could support a more comprehensive understanding of NSCLC and pave the way for the development of non-invasive, predictive models and personalized therapeutic strategies. In addition, we explore the specific contributions of these technologies in enhancing clinical decision-making for lung cancer patients, with particular attention to their potential in early diagnosis, treatment selection, and real-time monitoring.
PMID:41153258 | DOI:10.3390/diagnostics15202586
-
Nature - Issue - nature.com science feeds
-
We need a new Turing test to assess AI’s real-world knowledge
Nature, Published online: 29 October 2025; doi:10.1038/d41586-025-03471-0A fresh set of benchmarks could help specialists to better understand artificial intelligence.
We need a new Turing test to assess AI’s real-world knowledge
Nature, Published online: 29 October 2025; doi:10.1038/d41586-025-03471-0
A fresh set of benchmarks could help specialists to better understand artificial intelligence.-
Omics In Lung
-
Prospective proteomics for discovering biomarkers in lung adenocarcinoma: a literature review
Transl Cancer Res. 2025 Sep 30;14(9):6102-6117. doi: 10.21037/tcr-2025-1092. Epub 2025 Sep 26.ABSTRACTBACKGROUND AND OBJECTIVE: Lung adenocarcinoma (LUAD), as the main subtype of non-small cell lung cancer (NSCLC), faces clinical challenges including molecular heterogeneity, late diagnosis, and aggressive growth, leading to a low 5-year survival rate. Biomarkers are critical for early detection, accurate differentiation of benign/malignant lesions, and guiding personalized treatment strategies.
Prospective proteomics for discovering biomarkers in lung adenocarcinoma: a literature review
Transl Cancer Res. 2025 Sep 30;14(9):6102-6117. doi: 10.21037/tcr-2025-1092. Epub 2025 Sep 26.
ABSTRACT
BACKGROUND AND OBJECTIVE: Lung adenocarcinoma (LUAD), as the main subtype of non-small cell lung cancer (NSCLC), faces clinical challenges including molecular heterogeneity, late diagnosis, and aggressive growth, leading to a low 5-year survival rate. Biomarkers are critical for early detection, accurate differentiation of benign/malignant lesions, and guiding personalized treatment strategies. Proteomic technologies using liquid biopsy show potential by analyzing protein changes and post-translational modifications (PTMs) to identify novel biomarkers and unravel cancer mechanisms. This review examines proteomic advances in LUAD, compares platform strengths, lists validated protein markers, and discusses challenges like specificity and regulations. It aims to develop a precision medicine framework by integrating multi-omics data for improved diagnosis and treatment.
METHODS: This study conducted a literature review by searching the PubMed and Web of Science databases for original articles written in English from 2002 to 2025, using the keywords "lung adenocarcinoma" OR "LUAD" AND "biomarkers" AND "proteomics" OR "SomaScan" OR "spatial proteomics" to identify the latest research findings in the field of proteomics technology and LUAD biomarkers. The included studies mainly focused on the current landscape of biomarkers in the diagnosis, treatment, and prognosis of LUAD.
KEY CONTENT AND FINDINGS: This review discusses high-throughput methods for comprehensive protein profiling in accessible biospecimens (tissues, blood, urine) to identify biomarkers for LUAD. We systematically evaluate emerging proteomic strategies, including mass spectrometry (MS), proximity extension assays (PEAs), spatial proteomics techniques, and SomaScan platforms-coupled with innovative computational frameworks have revolutionized biomarkers discovery and their translational potential in developing precision diagnostics and targeted therapies. Additionally, the review addresses challenges in integrating proteomics with genomics, transcriptomics, and metabolomics, offering new methodologies and expanding research in life sciences. As technological advancements continue, it is anticipated that more potential biomarkers will be conducted to validate the broader application in LUAD treatment, addressing early-stage disease complexities and aiding in selecting more effective treatment strategies.
CONCLUSIONS: By synthesizing cutting-edge evidence on proteome-driven LUAD biomarkers, this review elucidates actionable strategies to refine early detection protocols and mechanism-informed personalized treatment frameworks, directly advancing precision oncology initiatives for this prevalent malignancy through biomarker-guided clinical decision-making and multi-omics integration.
PMID:41158224 | PMC:PMC12554480 | DOI:10.21037/tcr-2025-1092
-
STAT

-
STAT+: Natera, known for spotting cancer recurrence, wades into early detection
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today. BridgeBio notches another Phase 3 win BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calciu
STAT+: Natera, known for spotting cancer recurrence, wades into early detection
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. It seems everyone I know has been getting sick lately — hope you are all taking care of yourselves! Onto the news today.
BridgeBio notches another Phase 3 win
BridgeBio said this morning that its investigational drug succeeded in a late-stage trial of patients with autosomal dominant hypocalcemia type 1, a rare genetic condition that causes low calcium levels in the blood.
Continue to STAT+ to read the full story…


© Adobe
-
Journal of Medical Internet Research
-
Improving Recruitment Into Research Studies via Electronically Collected Patient-Entered Data: Mixed Methods Study
Background: Patient recruitment remains a critical challenge in clinical research. Although the integration of electronically collected patient-entered data within clinical practices enables innovative recruitment approaches, existing methods present challenges such as increased patient burden and potential violation of autonomy. A more nuanced approach involves identifying patient attributes associated with higher propensity for research participation, enabling research teams to efficiently pri
Improving Recruitment Into Research Studies via Electronically Collected Patient-Entered Data: Mixed Methods Study
-
cs.AI, q-bio.NC updates on arXiv.org
-
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor genera
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
-
cs.AI, q-bio.NC updates on arXiv.org
-
From Cross-Task Examples to In-Task Prompts: A Graph-Based Pseudo-Labeling Framework for In-context Learning
arXiv:2510.24528v1 Announce Type: new Abstract: The capability of in-context learning (ICL) enables large language models (LLMs) to perform novel tasks without parameter updates by conditioning on a few input-output examples. However, collecting high-quality examples for new or challenging tasks can be costly and labor-intensive. In this work, we propose a cost-efficient two-stage pipeline that reduces reliance on LLMs for data labeling. Our approach first leverages readily available cross-task